NEWS - Pagina 2 van 3 - Xenikos - Resetting the immune system

3 januari 2017

EUR 1 million innovation credit to support T-Guard® development

2 november 2016

Xenikos appoints Eric van Hooren as Chief Development Officer

25 oktober 2016

Xenikos to participate in BIO-Europe® International Partnering Conference

14 oktober 2016

New financing triggered by promising preliminary data from ongoing Phase 1/2 study

20 september 2016

Participation in 3PBio Forum technology transfer panel at BIOSPAIN 2016

15 september 2016

Last patient treated in Phase 1/2 trial with T-Guard® in acute GVHD disease

24 mei 2016

Introduction T-Guard® to potential pharmaceutical partners at BIO 2016

4 januari 2016

Graft versus Host Disease (GVHD) Study Delivers Promising Interim Results

1 oktober 2015

Clinical Study of T-Guard® in the Treatment of GVHD extends to Germany

//]]>